Login Register Cart 0
Generic placeholder image

Current Organic Synthesis

Editor-in-Chief

ISSN (Print): 1570-1794
ISSN (Online): 1875-6271

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Patent News

Recent Discovery of Triazine Derivatives as Protease Inhibitors for the Treatment of Coronavirus-19 (COVID-19)

Author(s): Surya K. De*

Volume 21, Issue 1, 2024

Published on: 22 May, 2023

Page: [91 - 95] Pages: 5

DOI: 10.2174/1570179420666230320120852

Price: $65

conference banner
Abstract

The present application describes a class of compounds exhibiting a coronavirus 3CL protease inhibitory effect and pharmaceutically acceptable salts thereof, and a pharmaceutical composition containing the same. The application also provides the synthesis of compounds and efficacy from in vitro and cell- based assays.

« Previous
Graphical Abstract

[1]
Malone, B.; Urakova, N.; Snijder, E.J.; Campbell, E.A. Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design. Nat. Rev. Mol. Cell Biol., 2022, 23(1), 21-39.
[http://dx.doi.org/10.1038/s41580-021-00432-z] [PMID: 34824452]
[2]
Liu, Y.; Liang, C.; Xin, L.; Ren, X.; Tian, L.; Ju, X.; Li, H.; Wang, Y.; Zhao, Q.; Liu, H.; Cao, W.; Xie, X.; Zhang, D.; Wang, Y.; Jian, Y. The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020. Eur. J. Med. Chem., 2020, 206, 112711.
[http://dx.doi.org/10.1016/j.ejmech.2020.112711] [PMID: 32810751]
[3]
Gulyaeva, A.A.; Gorbalenya, A.E. A nidovirus perspective on SARS-CoV-2. Biochem. Biophys. Res. Commun., 2021, 538, 24-34.
[http://dx.doi.org/10.1016/j.bbrc.2020.11.015] [PMID: 33413979]
[4]
Zumla, A.; Chan, J.F.W.; Azhar, E.I.; Hui, D.S.C.; Yuen, K.Y. Coronaviruses — drug discovery and therapeutic options. Nat. Rev. Drug Discov., 2016, 15(5), 327-347.
[http://dx.doi.org/10.1038/nrd.2015.37] [PMID: 26868298]
[5]
Ou, X.; Liu, Y.; Lei, X.; Li, P.; Mi, D.; Ren, L.; Guo, L.; Guo, R.; Chen, T.; Hu, J.; Xiang, Z.; Mu, Z.; Chen, X.; Chen, J.; Hu, K.; Jin, Q.; Wang, J.; Qian, Z. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat. Commun., 2020, 11(1), 1620.
[http://dx.doi.org/10.1038/s41467-020-15562-9] [PMID: 32221306]
[6]
La Monica, G.; Bono, A.; Lauria, A.; Martorana, A. Targeting SARS-CoV-2 main protease for treatment of COVID-19: Covalent inhibitors structure–activity relationship insights and evolution perspectives. J. Med. Chem., 2022, 65(19), 12500-12534.
[http://dx.doi.org/10.1021/acs.jmedchem.2c01005] [PMID: 36169610]
[7]
Alzyoud, L.; Ghattas, M.A.; Atatreh, N. Allosteric binding sites of the SARS-CoV-2 main protease: Potential targets for broad-spectrum anti-coronavirus agents. Drug Des. Devel. Ther., 2022, 16, 2463-2478.
[http://dx.doi.org/10.2147/DDDT.S370574] [PMID: 35941927]
[8]
Hu, Q.; Xiong, Y.; Zhu, G.H.; Zhang, Y.N.; Zhang, Y.W.; Huang, P.; Ge, G.B. The SARS-CoV-2 main protease (Mpro): Structure, function, and emerging therapies for COVID-19. MedComm, 2020, 3(3), e151.
[http://dx.doi.org/10.1002/mco2.151]
[9]
Dal-Ré, R.; Becker, S.L.; Bottieau, E.; Holm, S. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach. Lancet Infect. Dis., 2022, 22(8), e231-e238.
[http://dx.doi.org/10.1016/S1473-3099(22)00119-0] [PMID: 35364019]
[10]
Chia, C.S.B.; Xu, W.; Shuyi Ng, P. A patent review on SARS coronavirus main protease (3CLpro) inhibitors. Chem. Med. Chem., 2022, 17(1), e202100576.
[http://dx.doi.org/10.1002/cmdc.202100576] [PMID: 34651447]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy